Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia

Journal of Clinical Oncology

Volumn 20, Issue 3, 2002, Pages 674-679

  Rizzieri, David A ^a   Bass, Adam J ^a   Rosner, Gary L ^a   Gockerman, Jon P ^a   DeCastro, Carlos M ^a   Petros, William P ^a   Adams, David J ^a   Laughlin, Mary J ^a   Davis, Patti ^a   Foster, Traci ^a   Jacobson, Robert ^a   Hurwitz, Herbert ^a   Moore, Joseph O ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; MITOXANTRONE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG ACTIVATION; DRUG BLOOD LEVEL; DRUG RESPONSE; DRUG TOLERABILITY; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STEADY STATE; STOMATITIS; VOMITING;

ACUTE DISEASE; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA; LEUKEMIA, MYELOID, CHRONIC; MIDDLE AGED; MITOXANTRONE; NEURAL TUBE DEFECTS;

EID: 0036468032     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.3.674     Document Type: Article

References (25)

1. Acute leukemia
2. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype
3. Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors
4. Advanced breast cancer: A phase II trial with gemcitabine
5. Phase II trial of gemcitabine (2′,2′-defluorodeoxycytidine) in patients with adenocarcinoma of the pancreas
6. Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study
7. Phase II study of gemcitabine (2′,2′-defluorodeoxycytidine) in previously treated ovarian cancer patients
8. Phase II study of single agent gemcitabine in previously untreated patients with metastatic urothelial cancer
9. Gemcitabine: Metabolism, mechanisms of action, and self-potentiation
10. Action of 2′,2′-diflourodeoxycytidine in DNA synthesis
11. Pharmacologically directed design of the dose rate and schedule of 2′,2- difluorodeoxycytidine (gemcitabine) administration in leukemia
12. Saturation of 2′,2′-difluorodeoxycytidine 5′ triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine
13. Gemcitabine: A modulator of intracellular nucleotide and deoxynucleotide metabolism
14. Cellular elimination of 2′,2′-diflourodeoxycytidine 5′ triphosphate: A mechanism of selfpotentiation
15. Continual reassessment method: A practical design for phase I clinical trials in cancer
16. Some practical improvements in the continual reassessment method for phase 1 studies
17. Methods for dose funding studies in cancer clinical trials: A review and results of a Mono Carlo study
18. Treatment related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel
19. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia
20. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
21. Intensive postremission chemotherapy in adults with acute myeloid leukemia
22. Long term survival in acute myeloid leukemia
23. Treatment of high risk myelodysplastic syndromes with idarubicin and cytosine arabinoside supported by granulocyte colony stimulating factor (GM-CSF)
24. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and leukemia group B 9565
25. Mitoxantrone in the treatment of relapsed and refractory acute leukemia